Nexletol provides alternative for people who cannot tolerate, do not fully respond to statins
MONDAY, Feb. 24, 2020 (HealthDay News) — A new type of cholesterol-lowering drug that works differently than statins has been approved by the U.S. Food and Drug Administration.
Esperion Therapeutics Inc.’s Nexletol will provide an alternative for people who cannot tolerate or do not fully respond to statins such as Lipitor and Crestor, the Associated Press reported.
Nexletol is a daily pill approved for people with a genetic predisposition for high cholesterol and for heart disease patients who need to further reduce their bad cholesterol. The drug is to be taken at the highest dose patients can tolerate and is used in conjunction with a healthy diet, according to the FDA.
“This is a nice alternative” to statins, but statins will still be the first choice, Christie Ballantyne, M.D., cardiology chief at Baylor College of Medicine, told the AP. Ballantyne consults for Esperion and helped test Nexletol.
Last Updated: Feb 24, 2020
Copyright © 2020 HealthDay. All rights reserved.
